• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·4502.T
Held by 1 Guru
Share

Takeda Pharmaceutical Company Limited Stocks

¥ 5706Last Updated 28.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

¥ 54.80B

¥ 5706
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Data is available to registered users only
Data is available to registered users only

Portfolio Weight (%)

Data is available to registered users only

Change

Data is available to registered users only

Fund

Data is available to registered users only
Manager
Fund
Portfolio Weight (%)
Change
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Sign up, to see portfolios that hold this stock
Sign up, to see portfolios that hold this stock

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 4502.T is 6162 and suggests 9.1% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendati

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 21:28

Apple Is Preparing for a Breakthrough in the Smart Home Market — Bloomberg

28.07.2026 21:08

An Nvidia-backed fiber-optic manufacturer is heading for its worst day in 24 years. Why?

28.07.2026 21:00

SpaceX lost $1.2 trillion in market capitalization before its stock rebounded from its low

28.07.2026 19:40

"A Pure Expression of Power": How Christopher Nolan's "Odyssey" Will Change IMAX

28.07.2026 19:12

The Nasdaq 100 has entered a correction phase. The "Wall Street fear" index jumped

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026